Anzeige
Meldung des Tages: Diese Zahlen lügen nicht: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Citius Oncology News

Aktie
WKN:  A40K7E ISIN:  US17331Y1091 US-Symbol:  CTOR Branche:  Pharmazeutika Land:  USA
0,8645 $
+0,0545 $
+6,73%
0,7349 € 17.04.26
Depot/Watchlist
Marktkapitalisierung *
68,68 Mio. €
Streubesitz
-
KGV
-6,55
Index-Zuordnung
-

Citius Oncology News

31.03.26 - PR Newswire
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development PR Newswire
24.03.26 - PR Newswire
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts PR Newswire
10.03.26 - PR Newswire
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory ...
04.03.26 - PR Newswire
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell ...
13.02.26 - PR Newswire
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PR Newswire
13.02.26 - PR Newswire
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PR Newswire
11.02.26 - PR Newswire
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar PR Newswire
07.01.26 - PR Newswire
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
How $594B in Precision Tech is Cracking the Metastatic Cancer Code PR Newswire
05.01.26 - PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) PR Newswire
23.12.25 - PR Newswire
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire
10.12.25 - PR Newswire
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-​The-Market Under Nasdaq Rules PR Newswire
09.12.25 - PR Newswire
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-​The-Market Under Nasdaq Rules PR Newswire
04.12.25 - PR Newswire
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim PR Newswire
01.12.25 - PR Newswire
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) PR Newswire
25.11.25 - PR Newswire
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting PR Newswire
21.11.25 - PR Newswire
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration PR Newswire
20.10.25 - PR Newswire
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch PR Newswire
17.10.25 - PR Newswire
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR Newswire
16.10.25 - PR Newswire
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ PR Newswire
08.10.25 - PR Newswire
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 PR Newswire

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »